Treating refractory chronic graft-versus-host disease with extracorporeal photochemotherapy.
Extracorporeal photochemotherapy (ECP; photopheresis), an immunomodulatory therapy, has previously demonstrated promising results in treating chronic graft-versus-host disease (cGvHD). We treated six patients (ages 33-54 years) with long-standing refractory extensive-stage cGvHD. ECP was performed thrice weekly initially in all patients. Concomitant therapies included prednisone (n=6), tacrolimus (n=5), cyclosporin A (n=2), hydroxychloroquine (n=2), mycophenolate mofetil (n=1), and psoralen plus ultraviolet A radiation (n=1). After an average of 7.2 months (range, 2-13 months) of ECP, all patients experienced either improvement or stabilization in sclerodermatous skin changes, as well as partial improvements in liver enzyme levels. Skin softening occurred in four patients and was noted as early as 3-8 weeks into treatment. Two patients were able to taper steroid therapy, and two patients were able to taper ECP to twice weekly. ECP was well tolerated. Our results support those of previous studies, suggesting that ECP may be beneficial in patients with refractory cGvHD.
Bisaccia
E
E
Department of Dermatology, Columbia University College of Physicians and Surgeons, New York, New York, USA.
Palangio
M
M
Gonzalez
J
J
Adler
K R
KR
Rowley
S D
SD
Goldberg
S L
SL
D000328:Adult; D002908:Chronic Disease; D016572:Cyclosporine / Q000627:therapeutic use; D005363:Ficusin / Q000627:therapeutic use*; D006086:Graft vs Host Disease / Q000188:drug therapy*; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008875:Middle Aged; D010778:Photochemotherapy; D011241:Prednisone / Q000627:therapeutic use; D014466:Ultraviolet Rays
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D005363:Ficusin; D011241:Prednisone